Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance.
- NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_assertion description "[Thirteen primary NSCLC heterotransplant models were used to test four treatment regimens, including platinum-based chemotherapy with and without bevacizumab (VEGF-neutralizing antibody) or HDGF-H3 (HDGF-neutralizing antibody) and chemotherapy with bevacizumab and HDGF-H3.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance.
- NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_assertion evidence source_evidence_literature NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance.
- NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_assertion SIO_000772 23695169 NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance.
- NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_assertion wasDerivedFrom befree-2016 NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance.
- NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_assertion wasGeneratedBy ECO_0000203 NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance.
- befree-2016 importedOn "2016-02-19" NP1079519.RAqdu-qC7oxnwnhlg2U7KJZ4Mhw9mDTTAHlEDDMAFS8XI130_provenance.